A recent study has found that the anti-nausea medication Aprepitant may do more than just prevent vomiting during chemotherapy.
It could also improve survival rates in women with early-stage breast cancer.
The strongest benefits were seen in those with triple negative breast cancer, a more aggressive form of the disease.
Producers: